Taking a step forward in CAR T-cell therapy for acute myeloid leukaemia and myelodysplastic syndrome

Chong Chyn Chua¹, Kathleen Pao Lynn Cheok²

Affiliations

¹ Department of Haematology, The Alfred Hospital and Monash University, Melbourne, VIC, 3004, Australia; The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia; Department of Haematology, Northern Hospital, Melbourne, VIC, Australia. Electronic address: c.chua@alfred.org.au.
² Department of Haematology, University College Hospital London, London, UK; Cancer Institute, University College London, London, UK.

PMID: 36764324
DOI: 10.1016/S2352-3026(23)00002-9

Comment

Taking a step forward in CAR T-cell therapy for acute myeloid leukaemia and myelodysplastic syndrome

Chong Chyn Chua et al. Lancet Haematol. 2023 Mar.

. 2023 Mar;10(3):e161-e162.

doi: 10.1016/S2352-3026(23)00002-9. Epub 2023 Feb 7.

Authors

Chong Chyn Chua¹, Kathleen Pao Lynn Cheok²

Affiliations

¹ Department of Haematology, The Alfred Hospital and Monash University, Melbourne, VIC, 3004, Australia; The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia; Department of Haematology, Northern Hospital, Melbourne, VIC, Australia. Electronic address: c.chua@alfred.org.au.
² Department of Haematology, University College Hospital London, London, UK; Cancer Institute, University College London, London, UK.

PMID: 36764324
DOI: 10.1016/S2352-3026(23)00002-9

No abstract available

PubMed Disclaimer

Conflict of interest statement

CCC has served as an advisory board member for Pfizer and Sumitomo Pharma, and received honoraria from Bristol Myer Squibb and Astra Zeneca. KPLC has received honoraria from Kite Pharma and Gilead Sciences.

Comment on

CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
Sallman DA, Kerre T, Havelange V, Poiré X, Lewalle P, Wang ES, Brayer JB, Davila ML, Moors I, Machiels JP, Awada A, Alcantar-Orozco EM, Borissova R, Braun N, Dheur MS, Gilham DE, Lonez C, Lehmann FF, Flament A. Sallman DA, et al. Lancet Haematol. 2023 Mar;10(3):e191-e202. doi: 10.1016/S2352-3026(22)00378-7. Epub 2023 Feb 7. Lancet Haematol. 2023. PMID: 36764323 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- H1 Connect - Access expert opinions and insights on biomedical research.
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Taking a step forward in CAR T-cell therapy for acute myeloid leukaemia and myelodysplastic syndrome

Affiliations

Taking a step forward in CAR T-cell therapy for acute myeloid leukaemia and myelodysplastic syndrome

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical